- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr John Fox Emphasizes the Importance of Genetic Counseling Before, After Genetic Testing
Offering patients genetic counseling before and after they receive genetic testing is crucial for making sure they understand what the results mean, explained John Fox, MD, MHA, vice president of Clinical Transformation at Spectrum Health.
Offering patients genetic counseling before and after they receive genetic testing is crucial for making sure they understand what the results mean, explained John Fox, MD, MHA, vice president of Clinical Transformation at Spectrum Health.
Priority Health was among the earlier health systems to require genetic counseling alongside genetic testing. What lessons have you learned from this policy, and has the health system made any adjustments over the years?
Priority Health began requiring genetic counseling before genetic testing to ensure that patients understood what the purpose of the testing was and so they could better understand the results. We also require—although it’s hard to physically require it—that patients have post-testing counseling, as well. The goal is to make sure the patients understand the results of the test and that they can make informed decisions about how to use those results. I think we do a disservice to patients, and in fact we probably cause harm, when patients get a test result they don’t understand, which can induce anxiety and potentially unnecessary subsequent treatment.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Strategies for Improving Patient Access to Dermatology Care
March 22nd 2025Elizabeth Jones, MD, FAAD, highlights the persistent issue of insurance companies favoring expensive, newer medications over equally effective generics in dermatology, emphasizing the time-consuming prior authorization process and advocating for patient partnerships and systemic improvements.
Read More
How Mirdametinib Improves QOL for People With NF1-Associated Plexiform Neurofibromas
March 18th 2025Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements.
Read More
